Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cosmosoft has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution involves 1 distinct examiner and a single distinct art unit, showing a concentrated effort in this specific field. This focus suggests that the company is currently advancing a particular biological or pharmaceutical innovation through the patent office.
The busiest examiner is LOVE, TREVOR M, who is managing the pending office action. Since this examiner handles the total pending volume, the company's immediate patenting outcomes are tied to the specific feedback and requirements of this single official. It is essential for the company to understand the examiner's history with biotechnology claims to effectively navigate the pending office action. The resolution of this matter will be the primary factor in determining the company's short-term success in securing intellectual property rights.
With only a single distinct art unit involved, the prosecution process is streamlined but lacks the breadth of a more diversified portfolio. The company's entire active presence at the patent office is defined by this single point of contact. Consequently, the interaction with the current examiner and art unit will be the sole determinant of the company's progress in the current patent cycle. Practitioners should focus on building a strong technical case that addresses the specific concerns of this specialized examination group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOVE, TREVOR M | 1 | 43.0% | +26.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040468 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | LOVE, TREVOR M | 42d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040468 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | LOVE, TREVOR M | 1611 | §103 | Final Rejection | 42d | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial